Loading clinical trials...
Loading clinical trials...
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
Conditions
Interventions
Lucanthone
Temozolomide (TMZ)
+2 more
Locations
10
United States
UCSD Moores Cancer Center
La Jolla, California, United States
UCI Medical Center
Orange, California, United States
Dent Neurologic Institute
Amherst, New York, United States
Fairview Hospital Moll Cancer Center/Cleveland Clinic
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Hillcrest Hospital Hirsh Cancer Center/Cleveland Clinic
Mayfield, Ohio, United States
Start Date
June 19, 2012
Primary Completion Date
April 15, 2013
Completion Date
April 15, 2013
Last Updated
October 19, 2021
NCT05839379
NCT00083512
NCT07100730
NCT05756985
NCT05084430
NCT05083754
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions